TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

HEALOME

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

HEALOME

ST13

US500000079377294

Classe

5, 42

Pedido

79377294

Registro

8081459

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

50

Atualização mais recente

23/07/2026

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

5, 42

Data de depósito

27/02/2023

Data de registro

30/12/2025

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

30/12/2025

Última transação

23/07/2026

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Código do desenho

4

Tipo de titular

99

Localização do titular

GB

Examinador

LINDEMYER, ANKHI MUKHERJEA

Unidade examinadora

N50

Localização atual

FILE REPOSITORY (FRANCONIA)

Titulares e representantes

Titulares

Healome Therapeutics Ltd

Representantes

Nicole M. Meyer Dickinson Wright PLLC

Classificação técnica

Classes Nice

Classe 5Classe 42

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 5

Pharmaceutical preparations and substances and therapeutic pharmaceuticals for diseases, traumatic injury, perioperative care, and inflammation related to the eye; pharmaceutical preparations, substances and treatments in the nature of eye drops, solutions, gels, films impregnated with preparations for the treatment of ocular and dermal conditions, sterilized dressings, sprays, lubricants, and ointments used for treatment for ocular diseases and conditions; pharmaceutical preparations, substances and treatments in the nature of eye drops, solutions, gels, lubricants, and ointments used for treatment for ocular diseases, ocular surface diseases and dry eye disease; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations, substances and treatments in the nature of solutions, gels, films impregnated with preparations for the treatment of ocular and dermal conditions, sterilized dressings, sprays, and ointments used for treatment for dermal diseases and conditions; pharmaceutical preparations, substances and treatments in the nature of solutions, gels, films impregnated with preparations for the treatment of scars, wounds and orthopaedic conditions, and for use in medical aesthetics treatments, sterilized dressings, sprays, and ointments used for treatment for scar prevention, wound healing, medical aesthetics and orthopaedic conditions; therapeutic preparations and substances, namely, eye drops, ocular lubricants, solutions, gels, films impregnated with preparations for the treatment of ocular diseases, ocular conditions, ocular surface diseases and dry eye disease, sterilized dressings, sprays, lubricants, and ointments for the treatment of ocular diseases, ocular conditions, ocular surface diseases and dry eye disease; gels for medical eye care; therapeutic gels for medical eye care; gel and liquid drops, sprays, films for use as a delivery agent for drugs and for therapeutic pharmaceuticals, suspensions in the nature of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of ocular diseases and conditions, and substances in the nature of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of ocular diseases and conditions; gels, suspensions, and liquids in the nature of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of ocular diseases and conditions; gels, suspensions, liquids, and lubricants in the nature of pharmaceutical preparations and therapeutic preparations for the treatment of eye conditions and diseases; tear film substitutes to provide lubrication, provide protection, support homeostasis, and for use as a delivery agent for drugs and supplements in the treatment of ocular conditions; tear film substitutes to provide lubrication, provide protection, support homeostasis, and for use as a delivery agent for drugs and supplements for the treatment of eye conditions and diseases; gels, suspensions, liquids, and lubricants in the nature of pharmaceutical preparations and therapeutic preparations for the treatment of eye conditions, namely, glaucoma, cataracts, amblyopia, age-related macular degeneration and diabetes-related retinopathy; gels, suspensions in the nature of pharmaceutical preparations and therapeutic pharmaceuticals, and liquids for medical and therapeutic use, namely, for treating eye diseases, treating traumatic eye injury, and used in perioperative eye care; eye drops; eye ointment for medical use; medicated eye-washes; eye lotions for medical use; lubricating eye drops; medicated liquids for the treatment of ocular diseases and conditions; medicated ocular lubricants; tear film substitutes being pharmaceutical preparations for the treatment of ocular diseases, injuries and conditions; tear substitutes, namely, artificial tears for ocular diseases and conditions; tear film substitutes, being pharmaceutical preparations in the form of eye drops, solutions, gels, sprays, lubricants, ointments and artificial tears for treatment of ocular diseases and conditions

Classe 42

Scientific and technological services and research and design relating thereto, namely, scientific research in the field of treatment of eye diseases, injuries and conditions, treatment of dermal diseases, injuries and conditions, and in the field of biomaterials science; industrial scientific analysis and research services in the fields of eye care products and wound care products; product research and development services; scientific and technological services and research services relating thereto, namely, scientific research in the field of treatment of eye diseases, eye injuries and eye conditions, treatment of dermal diseases, injuries and conditions, and in the field of biomaterials science; scientific research services for medical, biomedical and therapeutic purposes in the fields of ocular surface diseases, dry eye diseases, ocular surface injury, corneal wounds, glaucoma; medical and bioscience research services in the fields of ocular surface diseases, dry eye diseases, ocular surface injury, corneal wounds, glaucoma; biomedical research services; scientific research and development services relating to ocular diseases, treatment and conditions; research and development services relating to orthopaedics; scientific research and development services relating to dermatology; scientific research and development services relating to dermal applications, such as scar prevention, wound healing, medical aesthetics; scientific research and development services relating to the treatment of diseases and conditions; scientific research services relating to the treatment of eye diseases and conditions; therapeutic research services, namely, scientific research in the field of eye diseases and eye injury; advisory, consultancy and information services relating to all the aforesaid.

Publicações

Histórico de despachos e eventos da marca no USPTO.

50 publicações encontradas

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

23/07/2026

FICS

FINAL DISPOSITION NOTICE SENT TO IB

06/07/2026

FIMP

FINAL DISPOSITION PROCESSED

06/07/2026

NREP

NEW REPRESENTATIVE AT IB RECEIVED

07/05/2026

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

30/03/2026

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

30/12/2025

R.PR

REGISTERED-PRINCIPAL REGISTER

30/12/2025

NREP

NEW REPRESENTATIVE AT IB RECEIVED

29/11/2025

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

11/11/2025

PUBO

PUBLISHED FOR OPPOSITION

11/11/2025

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

05/11/2025

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

10/10/2025

XAEC

EXAMINER'S AMENDMENT ENTERED

10/10/2025

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

10/10/2025

GNEA

EXAMINERS AMENDMENT E-MAILED

10/10/2025

CNEA

EXAMINERS AMENDMENT -WRITTEN

10/10/2025

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

10/09/2025

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

10/09/2025

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

10/09/2025

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

11/03/2025

GNRT

NON-FINAL ACTION E-MAILED

11/03/2025

CNRT

NON-FINAL ACTION WRITTEN

11/03/2025

OPNX

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

08/02/2025

DOCK

ASSIGNED TO EXAMINER

04/02/2025

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

22/01/2025

OPNR

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

22/01/2025

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

09/01/2025

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

09/01/2025

ERFR

TEAS REQUEST FOR RECONSIDERATION RECEIVED

09/01/2025

GNFN

NOTIFICATION OF FINAL REFUSAL EMAILED

09/07/2024

GNFR

FINAL REFUSAL E-MAILED

09/07/2024

CNFR

FINAL REFUSAL WRITTEN

09/07/2024

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

04/06/2024

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

04/06/2024

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

04/06/2024

RFNP

REFUSAL PROCESSED BY IB

03/01/2024

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

08/12/2023

RFRR

REFUSAL PROCESSED BY MPU

05/12/2023

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

05/12/2023

CNRT

NON-FINAL ACTION WRITTEN

04/12/2023

DOCK

ASSIGNED TO EXAMINER

28/11/2023

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

31/10/2023

ECDR

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

31/10/2023

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

31/10/2023

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

31/10/2023

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

31/10/2023

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

31/10/2023

MAFR

APPLICATION FILING RECEIPT MAILED

29/08/2023

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

25/08/2023

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

24/08/2023

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace HEALOME ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.